Clinical course of non-small cell lung cancer with concurrent MET exon 14 skipping and KRAS G12C mutations treated with sequential targeted therapies: a case report
Authors:
- Yu HasegawaYHYu Hasegawa
- Daichi FujimotoDFDaichi Fujimoto
- Tetsushi MaesakoTMTetsushi Maesako
- Mayuko TokudaMTMayuko Tokuda
- Tomoki HigashiyamaTHTomoki Higashiyama
- Akio TadaATAkio Tada
- Yoshiki NegiYNYoshiki Negi
- Taiichiro OtsukiTOTaiichiro Otsuki
- Koji MikamiKMKoji Mikami
- Ryo TakahashiRTRyo Takahashi
- Toshiyuki MinamiTMToshiyuki Minami
- Kozo KuribayashiKKKozo Kuribayashi
Open Access
- 7 March 2026
- journal article
- Published by Elsevier in International Journal of Lung Cancer
- Vol. 1 (2)
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancerLung Cancer, 2024
- Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung CancerJAMA Oncology, 2023
- Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100Journal of Clinical Oncology, 2023
- Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung CancerClinical Cancer Research, 2020
- Co-occurring genomic alterations in non-small-cell lung cancer biology and therapyNature Reviews Cancer, 2019
- Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung CancerClinical Cancer Research, 2018
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014